Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Driving sustainable margin outcomes

Eagers Automotive
3:27pm
February 22, 2024
APE delivered FY23 (vs pcp): revenue +15% to A$9.9bn; underlying NPBT +7% to A$433m; DPS +4% to 74cps. The result was in-line with expectations. Cost management was again a highlight, with APE able to absorb a significant step up in funding costs. ROS at 4.4% (-35bps due to acquisitions/mix) is sector leading. Revenue growth guidance of ~A$1bn (+10%) was provided, anchored by ~A$0.8bn from acquisitions. Whilst the order book has declined, it continues to give support to the near-term gross margin outlook. Plenty of med-term structural growth initiatives are in play across: consolidation; strategic industry alliances; leading the EV transition; sales channel optimisation; used vehicles; and new markets (offshore). There will be periods of cyclicality experienced through time, however APE is executing on building a sustainably higher earnings base. Add maintained.

1H24 earnings: On trend

Universal Store Holdings
3:27pm
February 22, 2024
UNI’s focus on offering high quality, fashionable apparel in a well presented store environment with high levels of service is paying off. Despite the challenges facing the consumer discretionary market, especially among the younger demographic, the 1H24 performance was highly resilient. Costs were well controlled and margins outperformed expectations, resulting in EBIT coming in 6% above forecast. The core youth consumer appears to be picking up. We have increased our FY24 EBIT estimate by 4% and reiterate our Add rating with an increased target price of $5.65.

Base in place, building future FUM

HMC Capital
3:27pm
February 22, 2024
HMC delivered a strong 1H result driven by growth in the platform (particularly unlisted/private equity funds which have delivered >20% ROE). FY24 pre-tax EPS guidance was provided which includes performance fees and investment gains. The new detail in the result was focussed around future growth areas which was outlined in tandem with a new divisional structure for HMC given the ongoing growth in the platform via the addition of Energy Transition, Capital Solutions and Digital Infrastructure. Areas under development also include global healthcare and private credit. HMC has also attracted high calibre, experienced people to lead. HMC has been a top performer within the sector with the share price +45% over the past year as the strategy continues to bear fruit. We acknowledge the FUM trajectory towards $20bn is becoming clearer with several new initiatives underway and management to execute. However given recent strong performance we move to a Hold rating post result with a revised PT of $7.25 and note there will be a detailed update on new funds with an investor day to be held in 2H24.

Weak headline result, but underlying trends are ok

MA Financial Group
3:27pm
February 22, 2024
MAF’s FY23 NPAT (~A$42m) was -32% on the pcp and ~-12% below consensus (A$47m). Headline result figures disappointed due mainly to higher costs than consensus. Broadly, the build of MA’s underlying business appears to be going ok. However, a difficult cyclical environment and the higher FY23 investment spend repeating in FY24, means upside here is more an FY25 story, in our view. We lower our MAF FY24F/FY25F EPS by -17%/-21% mainly on higher cost assumptions. Our PT is set at A$6.07 (previously A$6.25) on lower earnings estimates offset by a valuation roll-forward. We still see solid medium term value, and maintain our ADD call.

Aerospace & Defence gaining traction

PWR Holdings Limited
3:27pm
February 22, 2024
PWH’s 1H24 result was comfortably above our expectations with growth in Emerging Technologies the key highlight. Divisional revenue growth: Motorsports (ex-Emerging Tech) +5%, Aftermarket +7%, Emerging Technologies +88%, OEM +12%. Key positives: Aerospace & Defence revenue jumped 124% with a stronger pipeline compared to six months ago; EBITDA margin increased 110bp to 28.6% mainly due to an improved sales mix and increased operating efficiency; Balance sheet remains healthy with net cash (ex-leases) of $15.6m. Key negative: ROE fell 100bp to 26.7%. We make minor adjustments to FY24-26 earnings forecasts with EBITDA increasing by between 1-2% and underlying NPAT also rising by 1-2% Our target price increases to $14.25 (from $11.90) reflecting changes to earnings forecasts and a roll-forward of our model to FY25 forecasts. Add rating maintained. While the stock is not cheap (38.4x FY25F PE), we believe PWH is a high-quality business with a strong track record of growth. With a healthy pipeline of opportunities across all key segments (particularly Aerospace & Defence), we expect this growth trend to continue over the long term.

1H24 earnings: Earnings shrunk

The Reject Shop
3:27pm
February 22, 2024
First the good news. TRS outperformed most companies in our coverage universe with +2.3% LFL sales growth in 1H24 (although this was a little less than we had expected). The offering of well-priced every day essentials seems to have resonated with its customers, seeing both transaction and units growth over the period. This has resulted in a shift in sales mix away from general merchandising to the lower margin consumables. Sales momentum continued into the first 7 weeks of 2H24. Then the bad news. There was substantial shrinkage (shoplifting) over the course of the half, impacting EBIT by $4m, which was down 16% yoy. Without this impact, EBIT would have been flat. We maintain our ADD rating on TRS but reduce our target price to $5.40 (was $6.25) due to reduced earnings estimates in the current year.

Delivering on promised returns

Mitchell Services
3:27pm
February 22, 2024
The 1H result was in-line with quarterly reporting, with few surprises. The 2cps interim div reflects a 100% NPAT payout in excess of policy and complimenting accretion from the on-market buyback. The current ex-growth phase looks set to continue, supporting compelling forecast free cash flow yield (22-30%) and dividend yield (9-11%). At only (2.0x FY24F EV/EBITDA MSV still looks disregarded by the market. MSV trades at a sharp discount to direct peers and recent drilling M&A.

Still trying to adjust to the post-COVID world

Healius
3:27pm
February 22, 2024
FY24 underlying profit has been downgraded by double digits, given lower 2H expectations for Pathology volumes and benefits. While 1Q saw high single -digit Pathology volumes and double-digit benefit growth, momentum faded in 2Q, with both metrics tracking in the low single-digit range. It appears soft GP attendances, coupled with labour shortages and inflationary pressures, continue to conspire in holding back volumes. While management is aiming to accelerate Pathology restructuring to better match volumes with costs, activity to date seems to have done little to move the dial, putting greater uncertainty around a solution and complete near-term turnaround. We lower our FY24-26 estimates, with our target price decreasing to A$1.37. Hold.

Less than compelling

Clinuvel Pharmaceuticals
3:27pm
February 22, 2024
CUV’s posted a weaker than expected 1H24 result, with negligible top-line growth combined with a significant increase in the cost base (clinical activity, staff retention incentives and an increase in service roles) to meet future demand. While the top-line growth was disappointing, paired with large cost base increases and Board turnover it failed to inspire much confidence. Investors remain in the dark on US vs EU performance outside of cursory commentary. There was no discussion around capital management plans outside of stockpiling cash, now ~25% of the market cap. We downgrade our target price to A$16 p/s (from A$22 p/s) and recommendation moves to Hold, noting increased risk around board and disclosure. Traders may find an opportunity down here, but equally prepared to wait until a number of investor concerns are addressed.

Wasn’t RIO supposed to buy everyone?

Rio Tinto
3:27pm
February 21, 2024
An in-line CY23 result, although RIO hasn’t been immune to weakening metal prices (ex-iron ore) and global inflation pressures. Looks can be deceiving, but RIO commentary continues to run contrary to a popular view that the big miner might be an aggressive acquirer pursuing M&A. Despite the challenges, and capex in OTUG, RIO still generated FCF of US$7.7bn in CY23. We maintain a Hold rating on RIO, with a A$127ps Target Price.

News & Insights

Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more
Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more